inclusion criteria: * positive sars-cov-2 diagnostic test (rt-pcr or validated rapid antigen test) ≤72 hours prior to randomization * at least three of the following symptoms of at least moderate (score ≥2 as per covid-19 symptom diary) intensity: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills or sweats, feeling hot or feverish, nausea, vomiting, or diarrhea. * has symptoms consistent with mild or moderate covid-19, as determined by the investigator, with onset ≤5 days before dosing on day 1

inclusion criteria: * positive sars-cov-2 diagnostic test (rt-pcr or validated rapid antigen test) ≤72 hours prior to randomization * at least three of the following symptoms of at least moderate (score ≥2 as per covid-19 symptom diary) intensity: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills or sweats, feeling hot or feverish, nausea, vomiting, or diarrhea. * has symptoms consistent with mild or moderate covid-19, as determined by the investigator, with onset ≤5 days before dosing on day 1

inclusion criteria: - positive sars-cov-2 diagnostic test (rt-pcr or validated rapid antigen test) ≤72 hours prior to randomization - at least three of the following symptoms of at least moderate (score ≥2 as per covid-19 symptom diary) intensity: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills or sweats, feeling hot or feverish, nausea, vomiting, or diarrhea. - has symptoms consistent with mild or moderate covid-19, as determined by the investigator, with onset ≤5 days before dosing on day 1

inclusion criteria: - positive sars-cov-2 diagnostic test (rt-pcr or validated rapid antigen test) ≤72 hours prior to randomization - at least three of the following symptoms of at least moderate (score ≥2 as per covid-19 symptom diary) intensity: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills or sweats, feeling hot or feverish, nausea, vomiting, or diarrhea. - has symptoms consistent with mild or moderate covid-19, as determined by the investigator, with onset ≤5 days before dosing on day 1